SCLX: Utang jangka cendhak perusahaan Scilex

This price chart illustrates the price action of Scilex Holding Company (SCLX), which develops non-opioid pain management methods. Approved injectable forms and patches for long-term treatment provide the firm with a stable income. However, the business relies heavily on patent extensions and sales volume, while the 0.00 metric highlights the risk of high debt coupled with low operating profitability.

Institutional capital evaluates Scilex Holding Company (SCLX) through the lens of its ability to service current liabilities. This financial debt with a maturity of up to 12 months aggregates all short-term loans and borrowings, determining the issuer's immediate liquidity. The trend of this metric reveals risks of cash shortages. For the biotech sector, this is critical when financing environmentally safe waste disposal. The stability of this metric confirms the asset's financial resilience.